Haemonetics Co. (NYSE:HAE) Shares Acquired by First Hawaiian Bank

First Hawaiian Bank lifted its stake in shares of Haemonetics Co. (NYSE:HAE) by 55.2% during the second quarter, Holdings Channel reports. The firm owned 6,165 shares of the medical instruments supplier’s stock after purchasing an additional 2,192 shares during the quarter. First Hawaiian Bank’s holdings in Haemonetics were worth $510,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of HAE. Capital Research Global Investors grew its stake in Haemonetics by 2.3% in the first quarter. Capital Research Global Investors now owns 6,674,751 shares of the medical instruments supplier’s stock valued at $569,690,000 after purchasing an additional 151,183 shares in the last quarter. Vanguard Group Inc. raised its holdings in Haemonetics by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 5,406,309 shares of the medical instruments supplier’s stock valued at $462,293,000 after acquiring an additional 25,451 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Haemonetics by 3.2% in the 4th quarter. Wellington Management Group LLP now owns 3,268,083 shares of the medical instruments supplier’s stock worth $279,454,000 after buying an additional 101,029 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Haemonetics by 7.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 826,731 shares of the medical instruments supplier’s stock worth $70,697,000 after buying an additional 59,670 shares in the last quarter. Finally, Westfield Capital Management Co. LP grew its position in Haemonetics by 27.2% during the 4th quarter. Westfield Capital Management Co. LP now owns 712,061 shares of the medical instruments supplier’s stock worth $60,888,000 after acquiring an additional 152,098 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on HAE. Needham & Company LLC upgraded Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price target on the stock in a research report on Wednesday, June 12th. JMP Securities increased their price objective on Haemonetics from $115.00 to $125.00 and gave the company a “market outperform” rating in a research report on Friday, May 10th. Finally, Barrington Research increased their price objective on Haemonetics from $105.00 to $107.00 and gave the company an “outperform” rating in a research report on Friday, May 10th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $109.50.

Haemonetics Trading Down 3.6 %

Haemonetics stock traded down $3.25 during mid-day trading on Monday, hitting $86.60. 609,472 shares of the company’s stock were exchanged, compared to its average volume of 508,961. The company’s 50 day simple moving average is $86.93 and its 200-day simple moving average is $84.19. Haemonetics Co. has a fifty-two week low of $70.74 and a fifty-two week high of $97.97. The firm has a market capitalization of $4.41 billion, a P/E ratio of 37.79, a PEG ratio of 1.64 and a beta of 0.29. The company has a quick ratio of 1.50, a current ratio of 2.56 and a debt-to-equity ratio of 0.83.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, May 9th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.02. Haemonetics had a return on equity of 22.25% and a net margin of 8.98%. The business had revenue of $343.00 million for the quarter, compared to the consensus estimate of $329.53 million. During the same quarter in the previous year, the business earned $0.77 earnings per share. Haemonetics’s quarterly revenue was up 12.7% on a year-over-year basis. On average, equities analysts anticipate that Haemonetics Co. will post 4.57 earnings per share for the current year.

Insider Transactions at Haemonetics

In other news, insider Stewart W. Strong sold 686 shares of Haemonetics stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $95.11, for a total value of $65,245.46. Following the completion of the sale, the insider now directly owns 18,196 shares in the company, valued at $1,730,621.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, insider Stewart W. Strong sold 733 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $96.04, for a total transaction of $70,397.32. Following the completion of the transaction, the insider now directly owns 15,608 shares in the company, valued at $1,498,992.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Stewart W. Strong sold 686 shares of the company’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $95.11, for a total transaction of $65,245.46. Following the transaction, the insider now owns 18,196 shares of the company’s stock, valued at $1,730,621.56. The disclosure for this sale can be found here. Insiders sold a total of 31,523 shares of company stock worth $2,812,120 over the last quarter. Company insiders own 1.80% of the company’s stock.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.